Glassman Robert sold $559K of PHVS

Glassman Robert sold 14,493 shares of Pharvaris N.V. (PHVS) at $38.56 ($0.56M total) on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glassman Robert
Published Sep 21, 2026, 7:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The transaction reduces insider ownership, which may be interpreted as a bearish cue by short‑term traders.

02

Market read

Primary source insider sale; modest relevance for traders monitoring PHVS.

03

What to watch

The director still holds 10,500 shares, indicating continued confidence.

Relevance 4/10Novelty 4/10Timing: filing reported today

Background

Form 4 filings disclose insider transactions; a director sale via a pre‑arranged plan is a standard disclosure.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Director Robert Glassman sold 14,493 shares for $558,812 via a 10b5-1 plan on Sep 17, reducing his stake to 10,500 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

Director sales are often viewed as a bearish signal, especially when reducing holdings by ~58%.

Market effects

Minimal impact on the biotech sector; insider sales are company‑specific.

No broader regional effect.

Limited to investors tracking PHVS.

Counterpoint

The sale could be routine liquidity planning under a 10b5-1, not a negative signal.

Key entities

  • Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

  • Robert Glassman

    Director of Pharvaris who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.